Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Higher GPS linked to adverse pathology risk in men on active surveillance

09 Oct 2019

A higher Genomic Prostate Score (GPS) is a predictor of an increased risk of adverse pathology in patients who undergo radical prostatectomy after a period on active surveillance, as in those who undergo immediate prostatectomy, reports a study. The GPS is also associated with biochemical recurrence after radical prostatectomy.

The investigators identified patients on active surveillance at University of California-San Francisco who had Gleason score 3 + 3 or low volume (33 percent of fewer positive cores) Gleason score 3 + 4 prostate cancer, GPS testing at diagnostic or confirmatory biopsy, clinical stage T1/T2, prostate-specific antigen <20, and a clinical CAPRA (Cancer of the Prostate Risk Assessment) score <6.

Adverse pathology, defined as Gleason score 4 + 3 or greater, stage pT2a or greater or pN1, was the primary outcome. Biochemical recurrence, defined as two consecutive prostate-specific antigen measurements >0.05 ng/ml following radical prostatectomy, was the secondary outcome.

In total, 215 men were included. Of these, 179 (83 percent) were at low risk and 36 (17 percent) were at intermediate risk by CAPRA scoring. The median GPS was 26.4 (interquartile range, 18.8–34.6).

Multivariate analysis revealed an association between a higher GPS and an increased risk of adverse pathology at delayed radical prostatectomy (hazard ratio [HR] per 5 units, 1.16, 95 percent CI, 1.06–1.26; p<0.01). An association also existed between a higher GPS and an increased risk of biochemical recurrence (HR per 5 units, 1.10, 1.00–1.21; p=0.04).

“The GPS (Oncotype Dx® Genomic Prostate Score) test is an RNA expression assay which can be performed on prostate biopsies,” according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.